Stifel Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $14.61
Indivior | 8-K: Indivior Announces Results for the First Quarter Ended March 31, 2025; FY 2025 Guidance Unchanged
Indivior's Growth Potential and Resilience Amid Market Challenges: A Buy Recommendation
Earnings Call Summary | Indivior(INDV.US) Q1 2025 Earnings Conference
Indivior Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Express News | Indivior Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results
Indivior Logs Lower Q1 Net Income, Revenue
Indivior Reaffirms 2025 Guidance: Expects Net Revenue Of $995M-$1.025B Vs. $1.046B Est.; Sees Adj. Gross Profit Of $185M-$225M
Earnings Flash (INDV.L) INDIVIOR Posts Q1 EPS $0.38
Indivior Q1 Adj. EPS $0.41 Beats $0.24 Estimate, Sales $266.00M Beat $262.35M Estimate
Press Release: Indivior Announces Q1 2025 Financial Results
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Indivior (INDV) Receives a Buy From Craig-Hallum
Earnings Preview: Indivior to Report Financial Results Pre-market on April 24
AI replacing animal experiments? A message from the FDA has left "monkey breeders" feeling devastated, and experts state that "we are still far from the stage of implementation."
① The news that the USA FDA has publicly stated it will gradually replace animal testing requirements has led to an increase in the stock prices of AI pharmaceutical companies, impacting traditional drug evaluation CRO companies; ② Some believe this action represents a trend in Industry development. However, others believe that it is far from being implementable.
Indivior PLC Updates Share Capital and Voting Rights
Is Indivior PLC (INDV) the Best Stock to Buy According to Howard Marks' Oaktree Capital Management?
Indivior PLC Announces Change in Major Holdings
Indivior Insiders Placed Bullish Bets Worth US$1.42m
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.